604 research outputs found

    Heavy-Mass Behavior of Ordered Perovskites ACu3Ru4O12 (A = Na, Ca, La)

    Full text link
    We synthesized ACu3Ru4O12 (A = Na, Na0.5Ca0.5, Ca, Ca0.5La0.5, La) and measured their DC magnetization, AC susceptibility, specific heat, and resistivity, in order to investigate the effects of the hetero-valent substitution. A broad peak in the DC magnetization around 200 K was observed only in CaCu3Ru4O12, suggesting the Kondo effect due to localized Cu2+ ions. However, the electronic specific heat coefficients exhibit large values not only for CaCu3Ru4O12 but also for all the other samples. Moreover, the Wilson ratio and the Kadowaki-Woods ratio of our samples are all similar to the values of other heavy-fermion compounds. These results question the Kondo effect as the dominant origin of the mass enhancement, and rather indicate the importance of correlations among itinerant Ru electrons.Comment: 6 pages, 6 figures, to be published in J. Phys. Soc. Jp

    Estimate of pre-thermal quench non-thermal electron density profile during Ar pellet shutdowns of low-density target plasmas in DIII-D

    Get PDF
    The radial density profile of pre-thermal quench (pre-TQ) early-time non-thermal (hot) electrons is estimated by combining electron cyclotron emission and soft x-ray data during the rapid shutdown of low-density (ne≲1019m−3) DIII-D target plasmas with cryogenic argon pellet injection. This technique is mostly limited in these experiments to the pre-TQ phase and quickly loses validity during the TQ. Two different cases are studied: a high (10 keV) temperature target and a low (4 keV) temperature target. The results indicate that early-time, low-energy (∼10 keV) hot electrons form ahead of the argon pellet as it enters the plasma, affecting the pellet ablation rate; it is hypothesized that this may be caused by rapid cross field transport of argon ions ahead of the pellet or by rapid cross field transport of hot electrons. Fokker-Planck modeling of the two shots suggests that the hot electron current is quite significant during the pre-TQ phase (up to 50% of the total current). Comparison between modeled pre-TQ hot electron current and post-TQ hot electron current inferred from avalanche theory suggests that hot electron current increases during the high-temperature target TQ but decreases during the low-temperature target TQ. The uncertainties in this estimate are large; however, if true, this suggests that TQ radial loss of hot electron current could be larger than previously estimated in DIII-D

    1.14Tb/s DP-QPSK WDM polarization-diverse optical phase conjugation

    Get PDF
    Optical phase conjugation (OPC) of a polarization-multiplexed comb of 10x114Gb/s DP-QPSK signals has been demonstrated for the first time, occupying a spectral bandwidth of >1THz (~9nm). The nonlinear element employed for the OPC was highly nonlinear fiber (HNLF) optimized for the suppression of stimulated Brillouin scattering (SBS) and configured in a bi-directional loop offering polarization diversity. Pump power (each way about the loop) and input signal power to the OPC subsystem were optimized at 29.7dBm and + 3dBm respectively producing a Q2 penalty of ≤0.9dB over all conjugate wavelengths, polarizations and output OSNR (up to 20dB)

    Use of Ar pellet ablation rate to estimate initial runaway electron seed population in DIII-D rapid shutdown experiments

    Get PDF
    Small (2-3 mm, 0.9-2 Pa • m3) argon pellets are used in the DIII-D tokamak to cause rapid shutdown (disruption) of discharges. The Ar pellet ablation is typically found to be much larger than expected from the thermal plasma electron temperature alone; the additional ablation is interpreted as being due to non-thermal runaway electrons (REs) formed during the pellet-induced temperature collapse. Simple estimates of the RE seed current using the enhanced ablation rate give values of order 1-10 kA, roughly consistent with estimates based on avalanche theory. Analytic estimates of the RE seed current based on the Dreicer formula tend to significantly underestimate it, while estimates based on the hot tail model significantly overestimate it

    The first biosimilar approved for the treatment of osteoporosis

    Get PDF
    To demonstrate the clinical comparability between RGB-10 (a biosimilar teriparatide) and the originator, a comparative pharmacokinetic trial was conducted. The study was successful in establishing bioequivalence. Marketing authorisation for RGB-10 (Terrosa®) was granted by the European Medicines Agency in 2017.Teriparatide, the first bone anabolic agent, is the biologically active fragment of human parathyroid hormone. The imminent patent expiry of the originator will open the door for biosimilars to enter the osteology market, thereby improving access to a highly effective, yet prohibitively expensive therapy.Subsequent to establishing comparability on the quality and non-clinical levels between RGB-10, a biosimilar teriparatide, and its reference product (Forsteo®), a randomised, double-blind, 2-way cross-over comparative study (duration: four days) was conducted in 54 healthy women (ages: 18 to 55 years) to demonstrate the pharmacokinetic/pharmacodynamic (PK/PD) equivalence and comparable safety of these products. Extents of exposure (AUC0-tlast) and peak exposure (Cmax), as measured by means of ELISA, were evaluated as co-primary PK endpoints, and serum calcium levels, as measured using standard automated techniques, were assessed for PD effects. Safety was monitored throughout the study.The 94.12% CIs for the ratio of the test to the reference treatments, used due to the two-stage design (85.20-98.60% and 85.51-99.52% for AUC0-tlast and Cmax, respectively), fell within the 80.00-125.00% acceptance range. The calcium PD parameters were essentially identical with geometric mean ratios (GMRs) of 99.93% and 99.87% for AUC and Cmax, respectively. Analysis of the safety data did not reveal any differences between RGB-10 and its reference.Based on the high level of similarity in the preclinical data and the results of this clinical study, marketing authorisation for RGB-10 (Terrosa®) was granted by the European Medicines Agency (EMA) in 2017
    corecore